Literature DB >> 8240318

Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.

Y J Zhang1, W Jiang, C J Chen, C S Lee, S M Kahn, R M Santella, I B Weinstein.   

Abstract

Amplification of the chromosome 11q13 region occurs in several types of human cancer including esophageal, breast, lung, bladder and hepatocellular carcinoma (HCC). The gene cyclin D1 maps to this region in close proximity to two proto-oncogenes hst-1 and int-2. We previously demonstrated that cyclin D1 was not only amplified but also overexpressed in about 30% of human esophageal cancers. To investigate the role of cyclin D1 in human hepatocellular carcinoma (HCC), DNA from 30 HCC and 5 control liver tissues from Taiwan and also the HCC cells lines HepG2 and Hep3B, were examined for amplification of the cyclin D1 gene. A 3 to 20-fold amplification was found in 4 of the 30 (13%) HCC samples but not in any of the 5 control tissues or the 2 cell lines. Immunohistochemical analysis of cyclin D1 indicated overexpression of this protein in tumors that displayed gene amplification. Weak or negative staining was observed in the other HCC samples as well as in the control tissues and cell lines. These data suggest that increased expression of cyclin D1 may play an important role in the development of a subset of human HCC, perhaps by perturbing normal control of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240318     DOI: 10.1006/bbrc.1993.2350

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  55 in total

1.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Over-expression of cyclin D1 regulates Cdk4 protein synthesis.

Authors:  M A Parker; N G Deane; E A Thompson; R H Whitehead; S K Mithani; M K Washington; P K Datta; D A Dixon; R D Beauchamp
Journal:  Cell Prolif       Date:  2003-12       Impact factor: 6.831

Review 3.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

4.  Amplification and overexpression of the cyclin D1 gene in head and neck squamous cell carcinoma.

Authors:  X Wang; Z P Pavelic; Y Q Li; L Wang; L Gleich; K Radack; J L Gluckman; P J Stambrook
Journal:  Clin Mol Pathol       Date:  1995-10

5.  Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control.

Authors:  Christopher A Reed; Christopher N Mayhew; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

6.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.

Authors:  Toshiharu Sakurai; Shin Maeda; Lufen Chang; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

Review 7.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

8.  RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.

Authors:  C A Reed; C N Mayhew; A K McClendon; X Yang; A Witkiewicz; E S Knudsen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

9.  ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1.

Authors:  Nikhil Tyagi; Sachin K Deshmukh; Sanjeev K Srivastava; Shafquat Azim; Aamir Ahmad; Ahmed Al-Ghadhban; Ajay P Singh; James E Carter; Bin Wang; Seema Singh
Journal:  Mol Cancer Res       Date:  2017-11-08       Impact factor: 5.852

10.  Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.

Authors:  Zhangyong Hu; Zhipeng Zhou; Guolian Xiong; Yali Wang; Yi Lai; Lan Deng; Jinliang Yang
Journal:  Tumour Biol       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.